SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is scheduled to present and participate in one-on-one meetings at four investor conferences in November.
Stifel 2022 Healthcare Conference (in-person)
|
| Presentation Date: |
Tuesday, November 15, 2022 |
| Presentation Time: |
3:35 PM ET |
| Format: |
Formal presentation |
| Presenter: |
Dan Chevallard, Chief Operating Officer and Chief Financial Officer |
|
|
| 13th Annual Jefferies London Healthcare Conference (in-person) |
| Presentation Date: |
Wednesday, November 16, 2022 |
| Presentation Time: |
5:35 PM GMT / 12:35 PM ET |
| Format: |
Formal presentation |
| Presenter: |
Mark Rothera, President and Chief Executive Officer |
|
|
| Piper Sandler 34th Annual Healthcare Conference (in-person) |
| Presentation Date: |
Tuesday, November 29, 2022 |
| Presentation Time: |
10:30 AM ET |
| Format: |
Formal presentation |
| Presenter: |
Mark Rothera |
|
|
| 5th Annual Evercore ISI HealthCONx Conference (virtual) |
| Presentation Date: |
Wednesday, November 30, 2022 |
| Presentation Time: |
1:50 PM ET |
| Format: |
Fireside chat |
| Presenters: |
Mark Rothera and Lisa Rojkjaer, Chief Medical Officer |
A live webcast of each presentation will be available on the Investors section of the Viracta website under “Events and Webcasts” at https://viracta.investorroom.com/events-and-webcasts. The webcasts will be archived for at least 30 days following the presentation.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company focused on the treatment of virus-associated cancers. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent/metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
